Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
暂无分享,去创建一个
W. Gradishar | E. Rock | A. Musolino | H. Rugo | F. Cardoso | G. Curigliano | S. Im | T. Pluard | D. Yardley | T. Bachelot | M. Pegram | Shengyan Hong | J. Cortés | L. Salazar | G. Wright | Sutton Edlich | F. Ricci | G. S. Wright | M. Laurentiis | P. Kaufman